Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | LPL | P06858 | 12/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243207 | 0.91 | CA1 (0.61) | CA1CA2CA9LPLLIPG | |
| SCHEMBL661288 | 0.89 | LPL (0.59) | CA1CA2CA9LPLLIPG | |
| SCHEMBL17423486 | 0.84 | LIPG (0.46) | CA1CA2CA9LPLLIPG | |
| SCHEMBL14857542 | 0.84 | TDP2 (0.43) | CA1CA2CA9LPLLIPG | |
| SCHEMBL25658494 | 0.84 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL623833 | 0.84 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5899727 | 0.84 | LPL (0.65) | CA1CA2CA9LPLLIPG | |
| SCHEMBL4160336 | 0.83 | LIPG (0.69) | CA1CA2CA9LPLLIPG | |
| SCHEMBL368960 | 0.82 | LPL (0.71) | CA1CA2CA9LPLLIPG | |
| SCHEMBL14754517 | 0.82 | CA1 (0.53) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730009-B2 | Compound and organic light-emitting element comprising same | LG CHEM, LTD. | 2023-08-15 | — | — | US | disclosed |
| US-11730009-B2 | Compound and organic light-emitting element comprising same | LG CHEM, LTD. | 2023-08-15 | — | — | US | disclosed |
| EP-3330265-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2020-04-15 | — | — | EP | disclosed |
| CN-109970741-A | Amino pyridazine ketone compound as kinases inhibitor | 江苏恒瑞医药股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| CN-106573001-B | Aminopyridazinone compounds as protein kinase inhibitors | 江苏恒瑞医药股份有限公司 | 2019-01-29 | — | — | CN | disclosed |
| EP-3166608-B1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-20180251465-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| EP-3330265-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG Chem, Ltd. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| EP-3166608-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016007185-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007185-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251465-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | CA1 3988/4885CA2 3443/4885CA9 4100/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | CA1 3988/4885CA2 3443/4885CA9 4100/4885 |
| US-11730009-B2 | Compound and organic light-emitting element comprising same | CRY2, CRY1, NR2E3 | CA1 2482/4885CA2 3625/4885CA9 681/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | CA1 3988/4885CA2 3443/4885CA9 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.